Cynthia Timmers to Treatment Outcome
This is a "connection" page, showing publications Cynthia Timmers has written about Treatment Outcome.
Connection Strength
0.107
-
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100411.
Score: 0.021
-
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100426.
Score: 0.021
-
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res. 2020 07 01; 26(13):3117-3125.
Score: 0.019
-
KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer. J Natl Compr Canc Netw. 2019 05 01; 17(5):409-413.
Score: 0.017
-
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leuk Lymphoma. 2018 04; 59(4):1008-1011.
Score: 0.016
-
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun; 24(6):1150-1158.
Score: 0.014